Otsuka to buy VC-backed Visterra for about $430 mln
Otsuka has agreed to acquire Visterra, a developer of antibody-based therapies for the treatment of patients with kidney diseases and other hard-to-treat diseases, for about $430 million in cash. The deal is expected to close in the third quarter of this year. Visterra is backed by Polaris Partners, Flagship Pioneering, the Bill and Melinda Gates Foundation, MRL Ventures Fund, Vertex Ventures HC, Serum Institute of India Private Ltd., Temasek Holdings, Omega Funds, Cycad Group, Lux Capital, Alleghany Financial Group Ventures, CTI Life Sciences Fund and Alexandria Equities.
11 July 2018•4 mins read
